Cite
HARVARD Citation
Del Bello, A. et al. (2019). Anti‐IL‐2R blockers comparing with polyclonal antibodies: Higher risk of rejection without negative mid‐term outcomes after ABO‐incompatible kidney transplantation. Clinical transplantation. 33 (10), p. n/a. [Online].